دورية أكاديمية
أعرض في EDS

High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.

التفاصيل البيبلوغرافية
العنوان: High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.
المؤلفون: Valentin-Vega YA; Department of Cancer Genetics, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Barboza JA, Chau GP, El-Naggar AK, Lozano G
المصدر: Human pathology [Hum Pathol] 2007 Oct; Vol. 38 (10), pp. 1553-62. Date of Electronic Publication: 2007 Jul 24.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: W B Saunders Country of Publication: United States NLM ID: 9421547 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0046-8177 (Print) Linking ISSN: 00468177 NLM ISO Abbreviation: Hum Pathol Subsets: MEDLINE
أسماء مطبوعة: Publication: Philadelphia, PA : W B Saunders
Original Publication: Philadelphia, W B. Saunders Co.
مواضيع طبية MeSH: Carcinoma, Squamous Cell/*metabolism , Head and Neck Neoplasms/*metabolism , Nuclear Proteins/*metabolism , Proto-Oncogene Proteins/*metabolism, Amino Acid Sequence ; Blotting, Western ; Carcinoma, Squamous Cell/genetics ; Cell Cycle Proteins ; DNA Mutational Analysis ; Gene Expression ; Head and Neck Neoplasms/genetics ; Humans ; Immunohistochemistry ; Molecular Sequence Data ; Mutation ; Nuclear Proteins/genetics ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins c-mdm2/genetics ; Proto-Oncogene Proteins c-mdm2/metabolism ; Sequence Homology, Amino Acid ; Transfection ; Tumor Suppressor Protein p53/genetics
مستخلص: The p53 tumor suppressor is mutated in most human tumors. MDM2, a well-known inhibitor of p53, is overexpressed in a large number of tumors, suggesting that increased levels of MDM2 also contribute to tumorigenesis. A novel p53 inhibitor, MDM4, was more recently identified. The role of MDM4 in cancer development is not well understood. We set out to examine the levels of MDM4 by immunohistochemistry in head and neck squamous carcinomas (HNSC) to ask whether high MDM4 levels could contribute to its development and progression. In addition, MDM2 and p53 levels were examined to identify overlapping expression patterns. MDM4 is present at high levels in 50% of HNSC. In addition, overexpression of MDM2 was detected in 80% of tumors, many of which were also positive for MDM4. A subset of tumors displayed high levels of all 3 proteins. Sequencing of the p53 gene revealed that tumors with positive immunoreactivity for MDM2 or MDM4, some of which also had high levels of p53, did not carry mutations in this gene. Thus, the detection of p53 by immunohistochemistry was not synonymous with the presence of p53 mutations. Expression of both MDM2 and MDM4 in tumors without p53 mutations strongly suggests that MDM2 and MDM4 inhibit the activity of this tumor suppressor in HNSC.
References: Nature. 1995 Nov 9;378(6553):206-8. (PMID: 7477327)
Nature. 1992 Jul 2;358(6381):80-3. (PMID: 1614537)
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3226-31. (PMID: 16492743)
Nucleic Acids Res. 1998 Aug 1;26(15):3453-9. (PMID: 9671804)
Oral Oncol. 1999 Mar;35(2):209-16. (PMID: 10435158)
J Biol Chem. 1999 Dec 31;274(53):38189-96. (PMID: 10608892)
Adv Cancer Res. 2000;77:81-137. (PMID: 10549356)
Jpn J Cancer Res. 2000 Nov;91(11):1126-33. (PMID: 11092977)
Oncology. 1996 Jul-Aug;53(4):308-12. (PMID: 8692535)
EMBO J. 1996 Oct 1;15(19):5349-57. (PMID: 8895579)
Nat Med. 2004 Dec;10(12):1321-8. (PMID: 15558054)
Nucleic Acids Res. 1994 Sep;22(17):3551-5. (PMID: 7937055)
Nat Genet. 2001 Sep;29(1):92-5. (PMID: 11528400)
Oral Oncol. 1999 Jan;35(1):77-85. (PMID: 10211314)
Nature. 1997 May 15;387(6630):299-303. (PMID: 9153396)
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3232-7. (PMID: 16492744)
Hum Genet. 1998 Jun;102(6):681-6. (PMID: 9703430)
Circulation. 2007 Jun 12;115(23 ):2925-30. (PMID: 17533180)
Cancer Res. 2003 Dec 15;63(24):8664-9. (PMID: 14695178)
Mol Cell Biol. 2002 Aug;22(15):5527-38. (PMID: 12101245)
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Nov;94(5):593-600. (PMID: 12424454)
Nature. 1997 May 15;387(6630):296-9. (PMID: 9153395)
Oral Oncol. 1999 Jan;35(1):45-55. (PMID: 10211310)
J Biol Chem. 2000 Sep 8;275(36):28039-44. (PMID: 10827196)
Mol Cell Biol. 2000 Feb;20(3):1001-7. (PMID: 10629057)
FEBS Lett. 1997 Dec 22;420(1):25-7. (PMID: 9450543)
Cell. 1992 Jun 26;69(7):1237-45. (PMID: 1535557)
Nature. 1995 Nov 9;378(6553):203-6. (PMID: 7477326)
Science. 2004 Feb 6;303(5659):844-8. (PMID: 14704432)
Genomics. 1997 Jul 1;43(1):34-42. (PMID: 9226370)
J Oral Pathol Med. 2000 Oct;29(9):413-25. (PMID: 11016683)
Cancer Res. 2002 Jun 1;62(11):3221-5. (PMID: 12036937)
J Pathol. 1999 Jan;187(1):112-26. (PMID: 10341712)
J Clin Oncol. 2002 Jul 1;20(13):2980-7. (PMID: 12089228)
Oncogene. 2001 Jul 5;20(30):4041-9. (PMID: 11494132)
Mol Cell Biol. 2004 Jul;24(13):5835-43. (PMID: 15199139)
Cancer Res. 2001 Mar 1;61(5):1839-42. (PMID: 11280734)
Cancer Res. 1999 Dec 15;59(24):6091-6. (PMID: 10626796)
معلومات مُعتمدة: CA97007 United States CA NCI NIH HHS; P50 CA097007 United States CA NCI NIH HHS; CA009299 United States CA NCI NIH HHS; P50 CA097007-05 United States CA NCI NIH HHS; T32 CA009299 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Cell Cycle Proteins)
0 (MDM4 protein, human)
0 (Nuclear Proteins)
0 (Proto-Oncogene Proteins)
0 (Tumor Suppressor Protein p53)
EC 2.3.2.27 (MDM2 protein, human)
EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
تواريخ الأحداث: Date Created: 20070727 Date Completed: 20071113 Latest Revision: 20191210
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC2699677
DOI: 10.1016/j.humpath.2007.03.005
PMID: 17651783
قاعدة البيانات: MEDLINE
الوصف
تدمد:0046-8177
DOI:10.1016/j.humpath.2007.03.005